Want to see NERV full AI Analyst Report?

Minerva Neurosciences (NERV) Price & Analysis

620 Followers

NERV Stock Chart & Stats

$6.73

-$0.09(-3.83%)

At close: Jan 08 4:00 PM EST

$6.73

-$0.09(-3.83%)

Day’s Range― - ―

52-Week Range$1.76 - $12.46

Previous CloseN/A

Volume1.19K

Average Volume (3M)465.60K

Market Cap

$188.22M

Enterprise Value$251.30

Total Cash (Recent Filing)$78.16M

Total Debt (Recent Filing)$64.96M

Price to Earnings (P/E)―

Beta1.22

Next Earnings

Aug 04, 2026

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-29.16

Shares Outstanding46,588,710

10 Day Avg. Volume1,362,901

30 Day Avg. Volume465,600

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)-0.24

Price to Sales (P/S)0.00

P/FCF Ratio>-0.01

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$7.00

Price Target Upside4.01% Upside

Rating ConsensusHold

Number of Analyst Covering1

EPS Forecast (FY)-3.54

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Governance AlignmentUpdating the charter and bylaws to current Delaware and SEC universal proxy norms reduces legal friction, clarifies shareholder processes, and lowers governance uncertainty. Stronger legal framework and clarified forum selection are durable improvements that can ease activism, M&A friction, and investor relations over years.

Strengthened Business/legal LeadershipAdding an experienced Chief Business Officer/General Counsel enhances commercial deal-making, licensing negotiations, and regulatory/legal execution. Durable leadership upgrades improve strategic execution, partnering capacity, and risk management across long clinical development timelines.

Established ATM Financing And Clear Phase 3 TimingHaving an at-the-market program provides a standing, flexible capital source to fund pivotal trials without negotiating discrete financings. Combined with a defined Phase 3 timeline, this supports sustained trial execution planning and reduces immediate liquidity uncertainty through the multiyear development window.

Bears Say

No Revenue; Persistent LossesZero product revenue and ongoing operating losses mean the company remains fully dependent on R&D funding rather than commercial cash flow. This structural lack of recurring revenue extends reliance on financing, constrains reinvestment capacity, and increases dilution and refinancing risk over the medium term.

Negative Equity And Rising DebtNegative shareholders' equity and a recent step-up in debt materially weaken balance-sheet resilience. Elevated leverage reduces borrowing capacity, increases refinancing sensitivity, and heightens going-concern risk—structural constraints that impair strategic optionality over multiple quarters.

Deep Cash Burn; Reliance On External FundingSustained negative operating and free cash flows indicate high R&D burn that is not offset by noncash items. This durable cash consumption necessitates repeated financings, increasing dilution risk and placing execution of long trials at continued risk absent reliable funding sources or partnerships.

Minerva Neurosciences News

Fourteen new option listings and one option delisting on July 22nd

New option listings for July 22nd include Tradr 2X Short AAOI Daily ETF (AAOZ), Alpha Cognition Inc (ACOG),...

4d ago

ACOG

ARTV

Minerva management to meet with Citizens

Meeting to be held in Boston on July 16 hosted by Citizens. Published first on TheFly – the...

16d ago

NERV

Minerva Neurosciences Updates Governance Following 2026 Shareholder Meeting

Minerva Neurosciences ( ($NERV) ) has provided an announcement. On June 3, 2026, Minerva Neurosciences held its 2026...

2M ago

NERV

Minerva Neurosciences Launches ATM Offering to Fund Trial

Minerva Neurosciences ( ($NERV) ) has shared an announcement. On May 27, 2026, Minerva Neurosciences, Inc. entered into...

2M ago

NERV

Minerva Neurosciences Launches Key Phase 3 Test for Roluperidone in Schizophrenia

Minerva Neurosciences ($NERV) announced an update on their ongoing clinical study. Minerva Neurosciences is running a Phase 3...

2M ago

NERV

Tsao Maintains Hold on Minerva as Roluperidone Phase 3 Progress Balances Rising Losses; $7 Price Target Reaffirmed

H.C. Wainwright analyst Douglas Tsao reiterated a Hold rating on Minerva Neurosciences today and set a price target...

3M ago

NERV

NERV Earnings this Week: How Will it Perform?

Minerva Neurosciences (NERV) is scheduled to report 1st quarter earnings on 05/06/2026. Regarding Q1 estimates, Wall Street analysts...

3M ago

NERV

Minerva initiated with an Outperform at Citizens

Citizens initiated coverage of Minerva (NERV) with an Outperform rating and $14 price target Minerva is developing roluperidone...

3M ago

NERV

Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline

Minerva Neurosciences ( ($NERV) ) just unveiled an update. Minerva Neurosciences, Inc. announced that its 2026 annual meeting...

4M ago

NERV

Minerva Neurosciences Appoints New Chief Business Officer, Counsel

Minerva Neurosciences ( ($NERV) ) has shared an update. On March 30, 2026, Minerva Neurosciences reached a settlement...

4M ago

NERV

Minerva appoints Jim O’Connor as chief business officer

Minerva (NERV) announced a leadership transition with the appointment of Jim O’Connor as chief business officer, effective April...

4M ago

NERV

Minerva screens first patient in roluperidone trial

Minerva (NERV) announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial...

4M ago

NERV

Why Is the VTI ETF Down Today? Daily Snapshot – 3/12/26

The Vanguard Total Stock Market ETF ($VTI), which tracks the broader U.S. stock market, was down 1.1% at...

5M ago

MSS

Minerva price target raised to $7 from $4 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Minerva (NERV) to $7 from $4 and keeps a Neutral...

5M ago

NERV

NERV FAQ

What was Minerva Neurosciences’s price range in the past 12 months?

Minerva Neurosciences lowest stock price was $1.76 and its highest was $12.46 in the past 12 months.

What is Minerva Neurosciences’s market cap?

Minerva Neurosciences’s market cap is $188.22M.

When is Minerva Neurosciences’s upcoming earnings report date?

Minerva Neurosciences’s upcoming earnings report date is Aug 04, 2026 which is in 9 days.

How were Minerva Neurosciences’s earnings last quarter?

Minerva Neurosciences released its earnings results on May 05, 2026. The company reported -$2.86 earnings per share for the quarter, missing the consensus estimate of -$0.127 by -$2.733.

Is Minerva Neurosciences overvalued?

According to Wall Street analysts Minerva Neurosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Minerva Neurosciences pay dividends?

Minerva Neurosciences does not currently pay dividends.

What is Minerva Neurosciences’s EPS estimate?

Minerva Neurosciences’s EPS estimate is -0.19.

How many shares outstanding does Minerva Neurosciences have?

Minerva Neurosciences has 46,588,710 shares outstanding.

What happened to Minerva Neurosciences’s price movement after its last earnings report?

Minerva Neurosciences reported an EPS of -$2.86 in its last earnings report, missing expectations of -$0.127. Following the earnings report the stock price went down -1.264%.

Which hedge fund is a major shareholder of Minerva Neurosciences?

Currently, no hedge funds are holding shares in NERV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Minerva Neurosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

186.68%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Minerva Neurosciences

Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.

Minerva Neurosciences (NERV) Earnings & Revenues

Historic Earnings Reports

NERV Stock 12 Month Forecast

Average Price Target

$7.00

▲(4.01% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","2":"$2","4":"$4","6":"$6","8":"$8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,2,4,6,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.15,5.292307692307693,5.434615384615385,5.5769230769230775,5.719230769230769,5.861538461538462,6.003846153846154,6.1461538461538465,6.288461538461538,6.430769230769231,6.573076923076923,6.7153846153846155,6.857692307692307,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.15,5.292307692307693,5.434615384615385,5.5769230769230775,5.719230769230769,5.861538461538462,6.003846153846154,6.1461538461538465,6.288461538461538,6.430769230769231,6.573076923076923,6.7153846153846155,6.857692307692307,{"y":7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.15,5.292307692307693,5.434615384615385,5.5769230769230775,5.719230769230769,5.861538461538462,6.003846153846154,6.1461538461538465,6.288461538461538,6.430769230769231,6.573076923076923,6.7153846153846155,6.857692307692307,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.67,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.912,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.265,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.1,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.2,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.02,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.68,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.07,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.84,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.15,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >